KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Work In Process (2016 - 2025)

Resmed (RMD) has disclosed Work In Process for 16 consecutive years, with $968000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Work In Process fell 62.29% year-over-year to $968000.0, compared with a TTM value of $968000.0 through Dec 2025, down 62.29%, and an annual FY2025 reading of $2.6 million, down 6.01% over the prior year.
  • Work In Process was $968000.0 for Q4 2025 at Resmed, down from $2.0 million in the prior quarter.
  • Across five years, Work In Process topped out at $5.2 million in Q3 2023 and bottomed at $968000.0 in Q4 2025.
  • Average Work In Process over 5 years is $3.2 million, with a median of $3.2 million recorded in 2022.
  • Peak annual rise in Work In Process hit 77.67% in 2025, while the deepest fall reached 62.29% in 2025.
  • Year by year, Work In Process stood at $4.0 million in 2021, then decreased by 24.57% to $3.0 million in 2022, then fell by 2.42% to $2.9 million in 2023, then dropped by 12.75% to $2.6 million in 2024, then crashed by 62.29% to $968000.0 in 2025.
  • Business Quant data shows Work In Process for RMD at $968000.0 in Q4 2025, $2.0 million in Q3 2025, and $2.6 million in Q2 2025.